Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?

Tempus AI (TEM) significantly outperformed NVIDIA (NVDA) year-to-date, with shares surging 91.8% versus NVDA's 29.2%, driven by TEM's 75% Q1 revenue growth and a strategic $200 million oncology AI model partnership with AstraZeneca. While NVIDIA remains a critical AI infrastructure provider, expanding its healthtech footprint through platforms like Clara and drug discovery deals, Tempus AI's faster growth, expanding AI partnerships, and more attractive forward P/S ratio of 7.84 compared to NVDA's 18.96 position it as a potentially better short-term opportunity in the AI-health tech sector, despite both holding a Zacks #3 (Hold) rank.

Analysis

Tempus AI (TEM) is demonstrating significant operational momentum and market outperformance relative to NVIDIA (NVDA) within the specialized AI-healthcare sector. The company reported a 75% year-over-year revenue increase in Q1, propelled by an 89% surge in its genomics segment and a 43% rise in its data and services business. This growth is amplified by a strategic pivot from a diagnostics focus to a broader AI platform model, underscored by a $200 million partnership with AstraZeneca and Pathos to develop a large-scale oncology foundation model. This contrasts with NVIDIA's role as a foundational infrastructure provider, which is expanding its healthcare footprint through platforms like Clara and BioNeMo and partnerships with industry giants like Novo Nordisk. From a valuation perspective, Tempus AI appears more attractive, trading at a forward price-to-sales (P/S) ratio of 7.84, below its one-year median. In contrast, NVIDIA trades at a premium P/S of 18.96, above its recent median. While both companies have similar modest short-term upside based on analyst price targets (around 5%) and hold a Zacks #3 (Hold) rank, TEM's 91.8% year-to-date share price surge, compared to NVDA's 29.2%, reflects strong investor conviction in its focused growth strategy.

Key Decisions for Investors

• Investors seeking direct exposure to AI applications in precision oncology should evaluate Tempus AI, given its rapid 75% revenue growth, strategic platform shift, and relatively attractive valuation at a 7.84 forward P/S ratio.
• While NVIDIA remains a critical enabler of the AI ecosystem, its elevated valuation at a forward P/S of 18.96 may limit near-term upside, suggesting a more cautious stance for those specifically targeting the health-tech vertical.
• Despite TEM's strong momentum and outperformance, both stocks carry a Zacks #3 (Hold) rank and have similar, modest analyst price target upsides, signaling that investors should monitor execution on partnerships and data monetization before significantly increasing positions.